[63] Survodutide, Mazdutide, Pemvidutide, MariTide, Ecnoglutide, and Bimagrumab Other emerging therapies include dual GLP-1/glucagon receptor agonists such as survodutide, mazdutide, and pemvidutide, long-acting antibody-based or peptide-conjugate approaches such as maridebart cafraglutide (MariTide), biased GLP-1 receptor agonists such as ecnoglutide, and body-composition-targeted therapies such as bimagrumab, which targets activin type II receptors to reduce fat mass while preserving or increasing lean mass
Recombinant human Dnase I (rhDNase) in patients with lupus nephritis
But in other cases, it may cause dramatic and noticeable symptoms and behavior changes like convulsions, loss of consciousness and uncontrolled movement
Also, glucagon promotes lipolysis in adipose tissue, providing free fatty acids as an alternative energy source during periods of low glucose availability
Other precursor molecules like niacin and niacinamide (both forms of vitamin B3) may raise NAD+ levels, albeit not as effectively as NR or NMN
Best practices for building sustainable health habits [30:15]